AgomAb Therapeutics NV ADR (AGMB) Income Statement

33 Followers

AgomAb Therapeutics NV ADR Income Statement

Last quarter (Q4 2025), AgomAb Therapeutics NV ADR's total revenue was €0.00, a decrease of ― from previous quarter. In Q4, AgomAb Therapeutics NV ADR's net income was €-17.40M. See AgomAb Therapeutics NV ADR’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Mar 26
Total Revenue	€ 0.00
Gross Profit	€ 0.00
Operating Expenses	€ 59.27M
Depreciation and Amortization	€ 219.00K
EBITDA	€ -62.27M
Operating Income	€ -59.27M
Other Income/Expenses	€ -3.27M
Pretax Income	€ -62.55M
Net Income	€ -62.55M
Per Share Metrics
Basic EPS	€ -1.28
Diluted EPS	€ -1.28
Weighted Average Shares Outstanding	48.74M
Weighted Average Shares Outstanding (Diluted)	48.74M

Currency in EUR

AgomAb Therapeutics NV ADR (AGMB) Income Statement

AgomAb Therapeutics NV ADR Income Statement

AgomAb Therapeutics NV ADR Earnings and Revenue History